After securing all required regulatory approvals, Carl Zeiss Meditec has completed the 100 % acquisition of Dutch Ophthalmic Research Center from the investment firm Eurazeo, Paris, France. The move enhances and complements Zeiss Medical Technology’s broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, spanning retina and cornea disorders, cataract, glaucoma, and refractive errors.

“Today holds significant importance for us as we bring our teams together and turn our collective attention toward delivering breakthrough innovations and solutions for our customers. We are very excited to welcome D.O.R.C.’s team members to our Zeiss family and to begin integrating our products and practices as we work toward a brighter future together,” Dr Markus Weber, president and CEO of Carl Zeiss Meditec said on April 4th.

“Together we can offer an unmatched portfolio of advanced technologies and digital workflows. With DORC, we have an incredible opportunity to serve ophthalmologists around the world with more complete workflows and solutions than ever before,” says Dr Euan Thomson, president of ophthalmology and head of the digital business unit for Zeiss Medical Technology.

As a leading player in the retina surgical devices and consumables market, DORC’s contributions will be critical to Zeiss Medical Technology’s long-term strategy and success going forward. With DORC, Zeiss is in a unique position to offer an unmatched portfolio of market-leading technologies to ophthalmologists, including an expanded, digitally-connected retina surgery workflow from Zeiss

DORC brings to the acquisition one of the market’s most advanced dual-function systems – the EVA NEXUS platform, the core of a strong portfolio, comprising a full range of accessories, instruments and liquids, offering one of the best-in-class solutions across vitreo-retinal (VR) and combined cataract procedures.